A citation-based method for searching scientific literature

Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
Times Cited: 547



Michaël J B van Baar, Charlotte C van Ruiten, Marcel H A Muskiet, Liselotte van Bloemendaal, Richard G IJzerman, Daniël H van Raalte. Diabetes Care 2018
Times Cited: 86




List of shared articles



Times cited

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
Charlotte C van Ruiten, Mark M Smits, Megan D Kok, Erik H Serné, Daniël H van Raalte, Mark H H Kramer, Max Nieuwdorp, Richard G IJzerman. Cardiovasc Diabetol 2022
0

Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
6

Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
3

Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection.
Victor Chien-Chia Wu, Yan-Rong Li, Chao-Yung Wang. Int J Mol Sci 2021
2


Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
Rudolf A de Boer, Julio Núñez, Plamen Kozlovski, Yi Wang, Pieter Proot, Deborah Keefe. Br J Clin Pharmacol 2020
21

Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Harold E Bays, Plamen Kozlovski, Qing Shao, Pieter Proot, Deborah Keefe. Obesity (Silver Spring) 2020
10